

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2001-08-03** | Period of Report: **2001-08-03**  
SEC Accession No. **0000912057-01-526429**

([HTML Version](#) on [secdatabase.com](#))

FILER

**LIFE MEDICAL SCIENCES INC**

CIK: **889428** | IRS No.: **141745197** | State of Incorpor.: **DE** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: **000-20580** | Film No.: **1696802**  
SIC: **3842** Orthopedic, prosthetic & surgical appliances & supplies

Mailing Address  
379 THORNALL ST  
15TH FLOOR  
EDISON NJ 08837-2227

Business Address  
379 THORNALL ST  
EDISON NJ 08837-2227  
6094520707

<Page>

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 3, 2001

Commission File Number: 0-20580

LIFE MEDICAL SCIENCES, INC.  
-----

(Exact name of registrant as specified in its charter)

Delaware  
-----

(State of organization)

14-1745197  
-----

(I.R.S. Employer  
Identification No.)

P.O. Box 219, Little Silver, New Jersey 07739  
-----

(Address of principal executive office)

07739  
-----

(Zip Code)

(732) 494-0444  
-----

(Registrant's telephone number, including area code)

<Page>

ITEM 9. REGULATION FD DISCLOSURE

Contemporaneous with the filing of this Report, we are delivering the letter attached hereto as Exhibit 99.1 via electronic mail to stockholders, brokers and other groups included on our investor relations list. The filing of this report is not intended to constitute a representation that such filing is required by Regulation FD promulgated under the Securities Act of 1933, as

amended.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

- (a) Not Applicable.
- (b) Not Applicable.
- (c) The following Exhibits are filed as part of this Current Report on Form 8-K:

99.1 Letter of the Company dated August 2, 2001

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIFE MEDICAL SCIENCES, INC.

By: /s/ Robert P. Hickey

-----  
Robert P. Hickey  
Chairman of the Board of Directors,  
President and Chief Executive Officer

Dated: August 3, 2001

2

<Page>

EXHIBIT INDEX

<Table>

<Caption>

<S>

99.1 Letter of the Company dated August 2, 2001

Page No.  
<C>

</Table>

Dear Stockholder:

The recent distribution of the proxy statement in advance of the 2001 Annual Meeting of Stockholders, has generated interest in the status of activities at Life Medical Sciences. As you may recall, the company raised approximately \$1 million in December 2000 through the sale of Series A Convertible Preferred Stock to European institutional investors and the transfer of certain New Jersey State tax benefits. The principal use of these funds was intended to be the reactivation of the REPEL-CV(TM) Adhesion Barrier Film development program in cardiovascular surgical procedures.

I am please to report that progress has been made on all key aspects of the REPEL-CV development program in preparation for the planned initiation of a clinical efficacy trial later this year:

- Product manufacturing was successfully restarted and sterile product samples have been produced for use in the trial.
- The results of the previously conducted pilot clinical trial have been presented to the FDA.
- An ongoing productive dialogue has been established with the FDA regarding the protocol for the upcoming clinical trial.
- The initial clinical investigational sites have been identified for the trial.

We continue to see a high level of interest expressed by cardiovascular surgeons in having a product like REPEL-CV for use in open heart surgical procedures. In spite of the delays in this development program due to financial constraints, REPEL-CV may still be the first adhesion prevention product approved by the FDA for use in cardiovascular surgery. Although we believe our proprietary bioresorbable polymer materials may have application as anti-adhesion products in numerous types of surgical procedures, this exciting opportunity in cardiovascular surgery coupled with the outstanding preclinical efficacy results has lead us to focus on REPEL-CV.

We are in the midst of soliciting investment, primarily among European investors, in an equity offering. These securities have not been registered under the Securities Act of 1933 and may not be offered or sold in the US (or to a US person) absent registration or an applicable exemption from registration requirements. In addition, there are ongoing discussions with US investment groups regarding further funding requirements.

You may have noted that the slate of Directors standing for reelection numbers only five. Mr. Coy Eklund and Dr. Gere diZerega have chosen to retire from the Board and their positions will, for the near term, remain unfilled. Dr. diZerega will continue as Chairman of the company's Scientific Advisory Panel. On behalf of the remaining members of the Board, I would like to

express our appreciation for their dedication and many contributions.

Thanks to you, our stockholders, for your continued support.

Sincerely yours,

Robert P. Hickey  
Chairman, President & CEO